Table 2.
Incidence of invasive fungal infections (IFIs) in adult and pediatric patients.
| Hematologic malignancies | Adult patients | Pediatric patients | |
|---|---|---|---|
| Yeasts IFI No./Total (Incidence %) | Moulds IFI No./Total (Incidence %) | Yeasts IFI No./Total (Incidence %) | |
| AML | 8/195 (4.1) | 3/195 (1.5) | 0 |
| ALL | 1/48 (2.1) | 1/48 (2.1) | 2/88 (2.3) |
| CLL | 0 | 3/10 (30) | - |
| NHL | 2/140 (1.4) | 2/140 (1.4) | 1/7 (14.3) |
| HD | 0 | 1/5 (20) | 0 |
| MM | 2/72 (2.8) | 1/72 (1.4) | - |
| Host factors | |||
| Chemotherapy | 7/466 (1.5) | 5/466 (1.1) | 3/114 (2.6) |
| Central venous catheter | 9/238 (3.8) | 5/238 (2.1) | 3/105 (2.8) |
| Prolonged antibiotic therapy | 4/143 (2.8) | 2/143 (1.4) | 0 |
| Neutropenia <500 PMN/mm3 | 5/333 (1.5) | 9/333 (2.7) | 2/77 (2.6) |
| Neutropenia: 500–1000 PMN/mm3 | 1/142 (0.7) | 1/142 (0.7) | 1/37 (2.7) |
| Immunosuppressive therapy | 2/24 (8.3) | 1/24 (4.2) | 3/114 (2.6) |
| Corticosteroids | 0 | 4/95 (4.2) | 3/114 (2.6) |
| Parenteral nutrition | 4 (4.2) | 0 | 0 |
| Surgery | 1 (20) | 0 | 0 |
| Cytomegalovirus infection | 0 | 2/12 (16.7) | 0 |
| HSCT | |||
| Allogeneic bone marrow transplant | 1/15 (6.7) | 1/15 (6.7) | - |
| Autologous bone marrow transplant | 3/30 (10) | 0 | - |
AML: acute myeloid leukemia; ALL: acute lymphoid leukemia; CLL: chronic lymphocitic leukemia; NHL: non-Hodgkin’s lymphoma; HD: Hodgkin’s disease; MM: multiple myeloma; HSCT: hematopoietic stem cell transplantation.